Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders

Pathophysiology of Haemostasis and Thrombosis

Volumn 36, Issue 3-4, 2008, Pages 148-159

  Marchetti, Marina ^a,b   Falanga, Anna ^b,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b OSPEDALI RIUNITI   (Italy)

^c Department of Hematology/Oncology   (Italy)

Author keywords

Cytoreductive therapy; Essential thrombocythemia; Hemostatic system activation; JAK2V617F mutation; Leukocytosis; Myeloproliferative disorders; Polycythemia vera

Indexed keywords

JANUS KINASE 2; CYTOKINE; JAK2 PROTEIN, HUMAN; LEUKOCYTE ELASTASE;

ARTERY DISEASE; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; LEUKOCYTOSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SICKLE CELL; THROMBOCYTHEMIA; THROMBOSIS; VEIN THROMBOSIS; AMINO ACID SUBSTITUTION; BIOLOGICAL MODEL; BLOOD; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; GENETICS; INFLAMMATION; MALE; MISSENSE MUTATION; NEUTROPHIL; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; THROMBOCYTE ACTIVATION; THROMBOPHILIA; VASCULAR ENDOTHELIUM;

AMINO ACID SUBSTITUTION; CYTOKINES; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FEMALE; HEMOSTASIS; HUMANS; INFLAMMATION; JANUS KINASE 2; LEUKOCYTE ELASTASE; LEUKOCYTOSIS; MALE; MODELS, BIOLOGICAL; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; NEUTROPHILS; PLATELET ACTIVATION; POINT MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 61449140329     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000175153     Document Type: Review

References (70)

1. Gruppo Italiano Studio Policitemia: Polycy-themia vera: the natural history of 1,213 patients followed for 20 years. Ann Intern Med 1995;123: 656- 664.
2. Elliott MA, Tefferi A: Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128: 275-290.
3. Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W: Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycy t hemia vera: t herapeutic implications. Semin Thromb Hemost 2006;32:174-207.
4. Barbui T, Finazzi G: Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost 20 07;33: 321-329.
5. Coller BS: Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol 2005;25: 658- 670.
6. Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279: 14 7 7-14 8 2 .
7. Landolfi R, Di Gennaro L, Barbui T, et al: Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109:2446-2452.
8. Carobbio A, Finazzi G, Guerini V, et al: Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and JAK2 mutation status. Blood 2007;109:2310-2313.
9. Carobbio A, Antonioli E, Guglielmelli P, et al: Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008;26:2732-2736.
10. De Stefano V, Za T, Rossi E, et al: Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008;93:372-380.
11. Carobbio A, Finazzi G, Antonioli E, et al: Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008;112:3135-3137.
12. Lowe GD: Common risk factors for both arterial and venous thrombosis. Br J Haematol 2008;14 0 : 488-495.
13. Agnelli G, Becattini C: Venous thromboem-bolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost 2006;4:1886-1890.
14. Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Marziali S, Barbui T: Hemostatic system activation in patients with lupus anticoagulant and essential thrombocythemia. Semin Thromb Hemost 1994;20:324-327.
15. Falanga A, Marchetti M, Evangelista V, et al: Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266.
16. Wieczorek I, MacGregor IR, Ludlam CA: Low proteins C and S and activation of fibrinolysis in treated essential thrombocythemia. A m J Hematol 1995;49: 277-281.
17. Posan E, Ujj G, Kiss A, Telek B, Rak K, Udvardy M: Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia. Thromb Res 1998;90: 51-56 .
18. Cortelazzo S, Marchetti M, Orlando E, Falanga A, Barbui T, Buchanan MR: Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxy-genase pathway. Am J Hematol 1998;57:277-282.
19. Wheeler JG, Mussolino ME, Gillum RF, Danesh J: Associations between differential leucocyte count and incident coronary heart disease: 1,764 incident cases from seven prospective studies of 30,374 individuals. Eur Heart J 2004;25:1287-1292.
20. Naruko T, Ueda M, Haze K, et al: Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002;106: 2894-2900.
21. Falanga A, Marchetti M, Barbui T, Smith CW: Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 2005;42:239-247.
22. Afshar-Kharghan V, Thiagarajan P: Leukocyte adhesion and thrombosis. Curr Opin Hematol 2006;13:34-39.
23. 2 *). Curr Vasc Pharmacol 2004;2: 357-362.
24. Vischer UM, Jornot L, Wollheim CB, Theler JM: Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells. Blood 1995;85:3164-3172.
25. Camire RM, Kalafatis M, Tracy PB: Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding. Biochemistry 1998;37:11896-11906.
26. Plescia J, Altieri DC: Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. Biochem J 1996;319:873-879.
27. Evangelista V, Piccardoni P, White JG, de Gaetano G, Cerletti C: Cathepsin G-dependent platelet stimulation by activated polymorphonuclear leukocytes and its inhibition by antiproteinases: role of P-selectin-mediated cell-cell adhesion. Blood 1993;81:2947-2957.
28. Nemerson Y: Tissue factor in neutrophils. Thromb Haemost 2000;83: 802.
29. Giesen PL, Rauch U, Bohrmann B, et al: Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311-2315.
30. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA: The neutrophil as a cellular source of chemokines. Immunol Rev 2000;177:195-203.
31. Celi A, Pellegrini G, Lorenzet R, et al: P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994;91: 8767-8771.
32. De Gaetano G, Cerletti C, Evangelista V: Recent advances in platelet-polymorphonuclear leukocyte interaction. Haemostasis 1999;29:41-49.
33. Harlan JM, Killen PD, Harker LA, Striker GE, Wright DG: Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J Clin Invest 1981;68:1394-1403.
34. Kolpakov V, DAdamo MC, Salvatore L, et al: Neutrophil derived cathepsin G induces potentially thrombogenic changes in human endothelial cells: a scanning electron microscopy study in static and dynamic conditions. Thromb Haemost 1994;72: 140-145.
35. Falanga A, Marchetti M, Evangelista V, et al: Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999;93: 2506-2514.
36. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T: Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33: 523-530.
37. Higuchi DA, Wun TC, Likert KM, Broze GJ Jr: The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992;79: 1712-1719.
38. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC: Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001;66: 14 3-151.
39. Alvarez-Larran A, Garcia-Pagan JC, Abraldes JG, et al: Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br J Haematol 2004;124:329-335.
40. Villmow T, Kemkes-Matthes B, Matzdorff AC: Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 2002;108:139-145.
41. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in my-eloproliferative disorders. N Engl J Med 2005;352:1779-1790.
42. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
43. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythae-mia vera. Nature 2005;434: 114 4-114 8 .
44. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 20 05;365: 1054-1061.
45. Dupont S, Masse A, James C, et al: The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007;110: 1013-1021.
46. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL: JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108: 1652-1660.
47. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG: Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;1 0 7 : 4274- 4281.
48. Vannucchi AM, Antonioli E, Guglielmelli P, et al: Clinical profile of homozygous JAK2 617V>F mutation in patients with polycy-themia vera or essential thrombocythemia. Blood 2007;1 1 0 : 840-846.
49. Moliterno AR, Williams DM, Rogers O, Spivak JL: Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006;108:3913-3915.
50. Antonioli E, Guglielmelli P, Poli G, et al: Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008;93:41-48.
51. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC: The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis- impact on disease phenotype. Eur J Haematol 2007;79: 508-515.
52. Campbell PJ, Scott LM, Buck G, et al: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-1953.
53. Passamonti F, Randi ML, Rumi E, et al: Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 2007;110:485-489.
54. Finazzi G, Rambaldi A, Guerini V, Carobbio A, Barbui T: Risk of thrombosis in patients with essential thrombocythemia and poly-cythemia vera according to JAK2 V617Fmutation status. Haematologica 2007;92:135-136.
55. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C: The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006;132: 24 4-245.
56. De Stefano V, Fiorini A, Rossi E, et al: Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic my-eloproliferative disorders. J Thromb Haemost 2007;5: 708-714.
57. Rober tson B, Urquhart C, Ford I, et al: Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. J Thromb Haemost 2007;5:1679-1685.
58. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F: Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91: 16 9-17 5 .
59. Falanga A, Marchetti M, Vignoli A, et al: V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inf lammatory molecules. Exp Hematol 2007;35: 702-711.
60. Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC, et al: Increased platelet, leukocyte, and coagulation activation in primary my-elofibrosis. Ann Hematol 2008;87:269-276.
61. Muller I, Klocke A, Alex M, et al : Intrava scular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003;17:476-478.
62. Falati S, Liu Q, Gross P, et al: Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197: 1585-1598.
63. Myers DD, Hawley AE, Farris DM, et al: P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003;38: 1075-1089.
64. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY: Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circu lation 20 04;11 0 : 17 9 4-17 9 8 .
65. Rafail S, Ritis K, Schaefer K, et al: Leptin induces the expression of functional tissue factor in human neutrophils and peripheral blood mononuclear cells through JAK2-de-pendent mechanisms and TNF-αinvolvement. Thromb Res 2008;122: 366-375.
66. Marchetti M, Castoldi E, Spronk H, et al: Thrombin generation and activated protein C resistance in patients with essential throm-bocythemia and polycythemia vera. Blood 2008 (in press).
67. Cortelazzo S, Finazzi G, Ruggeri M, et al: Hydroxyurea for patients with essential throm-bocythemia and a high risk of thrombosis. N Engl J Med 1995;332: 1132-1136.
68. Harrison CN, Campbell PJ, Buck G, et al: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353: 33-4 5.
69. Maugeri N, Giordano G, Petrilli MP, et al: Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006;4:2593-2598.
70. Ricksten A, Palmqvist L, Johansson P, Andreasson B: Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 2008;93:1260-1261.